z-logo
Premium
Should providers prescribe sacubitril/valsartan based on trial eligibility, approval indication, or guideline recommendations?
Author(s) -
Ambrosy Andrew P.,
Fudim Marat,
Chioncel Ovidiu
Publication year - 2019
Publication title -
european journal of heart failure
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.149
H-Index - 133
eISSN - 1879-0844
pISSN - 1388-9842
DOI - 10.1002/ejhf.1555
Subject(s) - sacubitril , medicine , heart failure , valsartan , enalapril , sacubitril, valsartan , ejection fraction , guideline , cardiology , clinical trial , intensive care medicine , angiotensin converting enzyme , blood pressure , pathology

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom